Can a new pill tame immunotherapy's worst side effects and let patients restart treatment?
NCT ID NCT07313202
First seen Jan 07, 2026 · Last updated Jun 16, 2026 · Updated 24 times
Summary
This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safely restart their cancer treatment. The study has two parts: first, a safety check with a small group, then a larger group to measure how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ADVANCED SOLID TUMORS WHO DISCONTINUED TREATMENT DUE TO IRAE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.